Gilead adds GS-5816 to hepatitis C licensing deals in India
This article was originally published in Scrip
Executive Summary
Gilead Sciences added a third drug, GS-5816, to its licensing agreements with eight pharmaceutical manufacturers in India who have contracted to produce low-cost versions of the Foster City, California-based company's medicines for the hepatitis C virus (HCV) in developing countries.